Author(s):
Aarti J. Ahire, Shivraj P. Jadhav, Mayur S. Bhamare, Sunil K. Mahajan
Email(s):
aartiahire9011@gmail.com
DOI:
10.52711/2231-5659.2026.00055 
Address:
Aarti J. Ahire1*, Shivraj P. Jadhav2, Mayur S. Bhamare3, Sunil K. Mahajan4
1Department of Industrial Pharmacy, Sss’s Divine College of Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India.
2Department of Pharmaceutics, Sss’s Divine College of Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India.
3Department of Pharmaceutical Quality Assurance, Sss’s Divine College of Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India.
4Department of Pharmaceutical Chemistry, Sss’s Divine College of Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2026
ABSTRACT:
Background: Quality by Design (QbD) is a proactive, science based approach emphasizing systematic risk managed design in pharmaceutical development, moving away from traditional quality by testing methods. Objectives: To explore the historical and regulatory foundations of QbD (particularly ICH Q8–Q11), and to examine the core principles, tools, industrial implementations, benefits, challenges, and future directions of QbD in pharmaceutical development. Methods: Analysis and synthesis of multiple peer reviewed reviews and regulatory documents: including ICH Q8–Q11 guidelines, case studies, risk tools (e.g. FMEA, Ishikawa diagram), design of experiments (DoE), Process Analytical Technology (PAT), and control strategies. Applications and Case Studies: Demonstrated in small molecules, biologics, and advanced delivery systems; QbD enabled case studies have reported improved process understanding, streamlined formulation, robust scale up, faster approvals, and regulatory flexibility. Benefits: Improved quality consistency; enhanced manufacturing efficiency; reduced variability; lower regulatory burden; accelerated time to market; and robust lifecycle control. Challenges: High upfront costs; regulatory complexity and need for clear guidance; cultural and organizational change; data management challenges; and incomplete adoption in routine commercial manufacturing. Future Trends: Integration of digital tools, AI/machine learning, continuous manufacturing, advanced analytics, retrospective QbD, and automation frameworks is expected to further enhance QbD implementation. Conclusion: QbD represents a transformative shift in pharmaceutical development by embedding quality throughout the product lifecycle. While adoption faces hurdles, advances in regulatory alignment and digital innovation are poised to drive broader implementation and enhanced patient safety.
Cite this article:
Aarti J. Ahire, Shivraj P. Jadhav, Mayur S. Bhamare, Sunil K. Mahajan. A Comprehensive Review of Quality by Design (QbD) in Pharmaceutical Development and Manufacturing. Asian Journal of Research in Pharmaceutical Sciences. 2026; 16(4):381-8. doi: 10.52711/2231-5659.2026.00055
Cite(Electronic):
Aarti J. Ahire, Shivraj P. Jadhav, Mayur S. Bhamare, Sunil K. Mahajan. A Comprehensive Review of Quality by Design (QbD) in Pharmaceutical Development and Manufacturing. Asian Journal of Research in Pharmaceutical Sciences. 2026; 16(4):381-8. doi: 10.52711/2231-5659.2026.00055 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2026-16-4-8
9. REFERENCES:
1. Patil Karishma Ashok, Firke Sandip Dinkar. Determination and Development of UV-Spectrophotometric method for the Amodiquine Hydrochloride by using quality by design (QBD) approach. Asian J. Pharm. Ana. 2019; 9(3):113-117.
2. Vrushali R. Kadam, M. P. Patil, Vrushali V. Pawar, Sanjay Kshirsagar. A Review on: Quality by Design (QbD). Asian J. Res. Pharm. Sci. 2017; 7(4): 197-204.
3. Duarte JG. Rethinking Pharmaceutical Industry with Quality by Design. The AAPS J. 2025. doi:10.1208/s12248-025-01079 w SpringerLink
4. S. J. Daharwal. Development and Validation of UV Spectrophotometric Method for Simultaneous Estimation of Diazepam and Propranolol in Bulk Drug and Its Formulations. Asian J. Pharm. Ana. 2013; 3(1): 20-23.
5. B. Siddartha, I. Sudheer Babu, A. Krupalini, Prathyusha V. Development and Validation of UV– Spectrophotometric Method of Tolterodine in bulk and harmaceutical Dosage Form. Asian J. Pharm. Ana. 2013; 3(3): 102-104.
6. Nunavath RS, et al. Quality by Design in Pharmaceuticals: A Review. PubMed. 2024; abstract. (Article lacks DOI but is peer-reviewed) PubMedMrudula Kulkarni, Pratibha Dange, Sanjay Walode. Development and Validation of Difference Spectrophotometric Method for Zotepine in Bulk and Tablet Dosage Form. Asian J. Pharm. Ana. 2013; 3(3): 105-107.
7. Zagalo DM, Sousa J, Simões S. QbD approach in marketing authorization of non biological complex drugs. Eur J Pharm Biopharm. 2022; 178: 1–24. doi:10.1016/j.ejpb.2022.07.014 ResearchGate+13Wikipedia+13SpringerLink+13
8. Pallagi E, et al. New aspects of QbD for dry powder inhalation formulation. Int J Pharm. 2016; 511(1): 151–160. doi:10.1016/j.ijpharm.2016.07.003 Drug Delivery Journal+2SpringerLink+2IJPRA Journal+2
9. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009; 27(1): 26–34. doi:10.1038/nbt0109-26 Journal of Population Therapeutics+2Wikipedia+2SpringerLink+2
10. Hinz DC. Process analytical technologies in the pharmaceutical industry: FDA’s PAT initiative. Anal Bioanal Chem. 2006; 384(5):1036–1042. doi:10.1007/s00216 006 0402 0 Journal of Population Therapeutics+2Wikipedia+2SpringerLink+2
11. Ferreira AP, Tobyn M. Multivariate analysis in pharmaceutical industry: PAT and QbD era. Pharm Dev Technol. 2015; 20(5): 513–527. doi:10.3109/10837450.2014.949619 SpringerLink
12. Djuris J, Djuric Z. Modeling in QbD: Regulatory requirements for design space. Int J Pharm. 2017; 533(2): 346–356. doi:10.1016/j.ijpharm.2017.05.070 SpringerLink
13. Manzon D, et al. Comparison of design space construction methods in DoE. Chem Intell Lab Syst. 2020; 200: 104002. doi:10.1016/j.chemolab.2020.104002 SpringerLink+1MDPI+1
14. Siegfried ADAM, et al. DEM simulation approach for blending design space. Eur J Pharm Sci. 2011; 42(1): 106–115. doi:10.1016/j.ejps.2010.10.013 SpringerLink
15. Mitchell M. Criticality process parameters and quality attributes part I. BioPharm Int. 2013; 26(12). doi:— (industry whitepaper) SpringerLink+1Journal of Population Therapeutics+1
16. Mitchell M. Process control strategies—Criticality throughout lifecycle. BioPharm Int. 2014; 27(3). doi:— SpringerLink
17. Patil Divyashree Kantilal, Dhankani Amitkumar R, Dhankani Mansi A, S.P. Pawar. Optimizing Pharmaceutical Processes: A Comprehensive Review of Validation Strategies for Quality, Compliance and Efficiency. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(2): 177-1.
18. Saha M, et al. QbD based resveratrol loaded nanoparticles for ocular delivery. J Drug Deliv Sci Technol. 2021; 63: 102480. doi:10.1016/j.jddst.2021.102480 SpringerLink
19. Gupta MS, et al. Orodispersible films: Quality by Design. Adv Drug Deliv Rev. 2021; 178: 113983. doi:10.1016/j.addr.2021.113983 SpringerLink
20. Islam MT, et al. Sustained release formulations via hot melt extrusion, QbD approach. Drug Deliv Transl Res. 2014; 4(4): 377–387. doi:10.1007/s13346-014-0197-8 SpringerLink
21. Lee AR, et al. Bilayer combination tablet using QbD and high shear granulation. Int J Pharm. 2017; 534(1): 144–158. doi:10.1016/j.ijpharm.2017.10.004 SpringerLink
22. Qinglin Su, et al. Data reconciliation in continuous tablet manufacturing QbD. Int J Pharm. 2019; 563: 259–272. doi:10.1016/j.ijpharm.2019.04.003 SpringerLink
23. Jung EA, Park YJ, Kim JE. Continuous manufacturing for solid oral dosage QbD. J Pharm Investig. 2023; 53(4): 457–474. doi:10.1007/s40005-023-00619 w SpringerLink
24. Bostijn N, et al. Continuous manufacturing concept for oral suspension QbD. Eur J Pharm Sci. 2018; 123: 576–583. doi:10.1016/j.ejps.2018.08.015 SpringerLink
25. Prerana Musale, S. D. Mankar. Quality by Design Approch Based in Analytical Method Validation. Asian Journal of Pharmaceutical Analysis. 2023; 13(3): 190-6.
26. CH. Naveen Kumar, N. Kannappan. Development and validation of Bioanalytical Method for Quantification of phenytoin in rat brain tissues as per ICH guidelines. Asian J. Pharm. Ana. 2014; 4(4): 147-150.
27. Akhlaq M, et al. Dexibuprofen transdermal patches: QbD approach. J Drug Target. 2016; 24(7): 603–612. doi:10.3109/1061186X.2015.1116538 SpringerLink
28. Pooja L. Kumbhar, Anita S. Kulkarni, Rita D. Chakole, Manoj S. Charde. QbD Approach to Method Development, Validation and Degradation Profiling of Antifungal Drugs by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2024; 14(2): 69-5.
29. Vikram Gharge, Pranav Bang, Sachin Khopade, Krishna Kinage, Balasaheb Jadhav. Development and Validation of related Substances method for Deflazacort Suspension by High Performance Liquid Chromatography using AQbD Approach. Asian Journal of Pharmaceutical Analysis. 2025; 15(1): 31-9.
30. Shweta Jogdand, Karuna Mane, Rohit Jadhav, G K Dyade. AQBD Approach in Chemo metric assisted Method Development for the Estimation of Ciprofloxacin and Metronidazole by UV-VIS Spectrophotometry. Asian Journal of Pharmaceutical Research. 2022; 12(3): 183-1.)
31. Sushila D. Chavan, Nayana V. Pimpodkar, Amruta S. Kadam, Puja S.Gaikwad. Quality by Design. Asian J. Res. Pharm. Sci. 2016; 6(1): 45-50.